Asset profile
BMS-984923
Small molecule
Evidence outlook · lead readout
NCT04805983 · Alzheimer Disease
The reported results come from study designs that frequently fail to replicate under controlled conditions — see the rationale below.
NCT04805983: All participants received active drug at one of six doses with no placebo or control group, so there was no basis for comparison; the study was designed to characterize safety, drug levels and target engagement rather than to test whether the drug produced a clinical benefit.
Also in development:Parkinson's Disease · Phase 1
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Unlock the complete ClinicalTrials.gov registry
Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.
Competitive landscape
Unlock the competitor landscape
Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.